+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Giant cell arteritis (GCA) Market Insights, Epidemiology and Market Forecast - 2028

  • ID: 4871920
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 147 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • AbbVie
  • Genentech
  • Novartis Pharmaceuticals
  • Sanofi
  • MORE
'Giant cell arteritis (GCA) - Market Insights, Epidemiology and Market Forecast - 2028' report delivers an in - depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of GCA in the 7MM covering the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom) and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Giant cell arteritis (GCA) from 2017 to 2028 segmented by seven emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017 - 2028

Giant cell arteritis (GCA) - Disease Understanding

Giant cell arteritis (GCA) is the most common form of medium and large - vessel vasculitis. Inflammation typically affects head and neck arteries, including the superficial temporal and posterior ciliary arteries. Symptoms are caused by local vascular ischemia often combined with cytokine - mediated features.

GCA remains a medical emergency because of the risk of sudden, irreversible sight loss and stroke. It is a spectrum of phenotypically overlapping conditions, including cranial GCA, extracranial GCA (otherwise termed large - vessel GCA, usually involving the aorta and its larger supra - aortic branches), and polymyalgia rheumatica (PMR).

The Giant cell arteritis (GCA) market report gives the thorough understanding of the Giant cell arteritis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms for Giant cell arteritis in the 7MM.

Giant cell arteritis Epidemiology

The Giant cell arteritis (GCA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven countries in the report. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalence of Giant Cell Arteritis in 7MM, Sub - type specific prevalence of Giant Cell Arteritis, Gender Specific Diagnosed prevalence of Giant Cell Arteritis, Age Specific Diagnosed prevalence of Giant Cell Arteritis, Clinical Manifestations associated with Giant Cell Arteritis) scenario of Giant Cell Arteritis (GCA) in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and the United Kingdom) and Japan from 2017 - 2028.

According to this research, Total prevalent population of Giant Cell Arteritis in 7 MM was observed to be 423,131 cases in 2017.

Giant Cell Arteritis Drug Chapters

This segment of the Giant Cell Arteritis report encloses the detailed analysis of marketed drugs and late stage (Phase - III and Phase - II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Drugs that would bridge the unmet need for adjunctive therapy in order to combat the issues of side effects of GC, prolonged period of GC tapering and the risk of relapse during the tapering off cycle are being especially actively investigated.

Giant Cell Arteritis Market Outlook

The Giant Cell Arteritis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late - stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Giant Cell Arteritis in 7MM was found to be USD 862.90 Million in 2017, and is expected to increase during the course of the study period (2017 - 2028). United States accounts for the largest market size of Giant Cell Arteritis, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Giant Cell Arteritis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 - 2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Giant Cell Arteritis Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Giant Cell Arteritis Report Key Strengths
  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake
Giant Cell Arteritis Report Assessment
  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Giant Cell Arteritis market
  • Organize sales and marketing efforts by identifying the best opportunities for Giant Cell Arteritis market
  • To understand the future market competition in the Giant Cell Arteritis market.
Note: The publisher understands the needs of the rapidly changing market and the publisher is helping the client by providing the most up to date Report.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie
  • Genentech
  • Novartis Pharmaceuticals
  • Sanofi
  • MORE
1. Key Insights

2. Giant cell arteritis Market Overview at a Glance
2.1. Market Share (%) of Giant cell arteritis in 2017 - 7MM
2.2. Market Share (%) of Giant cell arteritis in 2028 - 7MM

3. Disease Background and Overview
3.1. Introduction
3.2. Etiology and risk factors
3.3. Signs and Symptoms associated with GCA
3.4. Pathophysiology
3.5. Clinical manifestations
3.6. Diagnosis
3.7. Molecular biomarkers in GCA patients important for diagnosis and prognosis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent Cases of Giant Cell Arteritis in 7MM

5. Country Wise-Epidemiology
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalence of Giant Cell Arteritis in the United States
5.1.3. Sub-type specific prevalence of GCA in the United States
5.1.4. Gender Specific Diagnosed prevalence of GCA in the United States
5.1.5. Age Specific Diagnosed prevalence of GCA in the United States
5.1.6. Clinical Manifestations associated with GCA in the United States
5.2. EU-5
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
5.3. Japan
5.3.1. Assumptions and Rationale
5.3.2. Prevalence of Giant Cell Arteritis in Japan
5.3.3. Sub-type specific prevalence of GCA in Japan
5.3.4. Gender Specific Diagnosed prevalence of GCA in Japan
5.3.5. Age Specific Diagnosed prevalence of GCA in Japan
5.3.6. Clinical Manifestations associated with GCA in Japan

6. Treatment and Management
6.1. The new era for GCA: Biologic Agents
6.2. Patient Journey

7. Unmet needs

8. Case Studies
8.1. Biopsy proven giant cell arteritis in a patient with psoriatic arthritis
8.2. Delayed Diagnosis of Giant Cell Arteritis in the Setting of Isolated Lingual Necrosis.
8.3. Case Study: Giant Cell Arteritis
8.4. Case Study: Giant Cell Arteritis
8.5. Giant Cell Arteritis: A Rare Disease in Asians

9. Marketed drugs
9.1. Tocilizumab (Actemra): Genentech
9.1.1. Product Description
9.1.2. Product Development Activities
9.1.3. Clinical development
9.1.4. Safety and Efficacy
9.1.5. Product Profile

10. Emerging drugs
10.1. Key Cross Competition
10.2. KPL-301: Kiniksa Pharmaceuticals, Ltd.
10.2.1. Product Description
10.2.2. Product Development Activities
10.2.3. Clinical development
10.2.4. Clinical Trials Information
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.3. Upadacitinib: AbbVie
10.3.1. Product Description
10.3.2. Clinical development
10.3.3. Clinical Trials Information
10.3.4. Product Profile
10.4. Secukinumab: Novartis Pharmaceuticals
10.4.1. Product Description
10.4.2. Other Development Activities
10.4.3. Clinical Development
10.4.4. Clinical Trials Information
10.4.5. Safety and Efficacy
10.4.6. Product Profile
10.5. Sarilumab: Sanofi
10.5.1. Product Description
10.5.2. Other Developmental Activities
10.5.3. Clinical Development
10.5.4. Clinical Trials Information
10.5.5. Product Profile

11. Other products of interest
11.1. Abatacept (CTLA-4Ig)
11.1.1. Product Description
11.1.2. Clinical development
11.1.3. Clinical Trials Information
11.1.4. Safety and Efficacy
11.1.5. Product Profile
11.2. Ustekinumab
11.2.1. Product Description
11.2.2. Clinical development
11.2.3. Clinical Trials Information
11.2.4. Product Profile

12. Giant cell arteritis: 7 Major Market Analysis
12.1. Key Findings
12.2. Market Size of Giant cell arteritis in 7MM
12.3. Market Scenario: 7MM

13. The United States Market Outlook
13.1. United States Market Size
13.1.1. Total Market size of Giant cell arteritis
13.1.2. Market Size by Therapies

14. EU-5 Countries: Market Outlook
14.1. Germany
14.1.1. Total Market size of Giant cell arteritis in Germany
14.1.2. Market Size by Therapies
14.2. France
14.2.1. Total Market Size of Giant cell arteritis
14.2.2. Market Size by Therapies
14.3. Italy
14.3.1. Total Market Size of Giant cell arteritis
14.3.2. Market Size by Therapies
14.4. Spain
14.4.1. Total Market Size of Giant cell arteritis
14.4.2. Market Size by Therapies
14.5. The United Kingdom
14.5.1. Total Market Size of Giant cell arteritis
14.5.2. Market Size by Therapies

15. Japan: Market Outlook
15.1. Japan Market Size
15.1.1. Total Market Size of Giant cell arteritis
15.1.2. Market Size by Therapies

16. Market drivers

17. Market Barriers

18. Appendix
18.1. Report Methodology

19. Publisher Capabilities

20. Disclaimer

21. About the Publisher
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Sanofi
  • Novartis Pharmaceuticals
  • Genentech
  • Kiniksa Pharmaceuticals, Ltd.
  • AbbVie
Note: Product cover images may vary from those shown
Adroll
adroll